« Back
Home /
Degarelix

Degarelix

Item no.	HY-16168A-100mg
Manufacturer	MedChem Express
CASRN	214766-78-6
Amount	100 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 2 mg 50 mg 5 mg
Category	Oncology Food Safety Hormones Inhibitors & Compound Libraries Small Molecules By Organ Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Purity	99.94
Formula	C82H103ClN18O16
Citations	[1]Rick FG, et al. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther. 2013 Apr 16;6:391-402. [2]Sakai M, et al. In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonistdegarelix on human prostate cell growth. PLoS One. 2015 Mar 26;10(3):e0120670. [3]Broqua P, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormoneantagonist: degarelix. J Pharmacol Exp Ther. 2002 Apr;301(1):95-102. [4]Sonesson A, et al. Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey. Drug Metab Dispos. 2011 Oct;39(10):1895-903. [5]Anders Sonesson, et al. In Vitro and In Vivo Human Metabolism of Degarelix, a Gonadotropin-Releasing Hormone Receptor Blocker. Drug Metabolism and Disposition. July 2013, 41 (7) 1339-1346. [6]Degarelix.
Smiles	C[C@H](C(N)=O)NC([C@H]1N(C([C@H](CCCCNC(C)C)NC([C@H](CC(C)C)NC([C@@H](CC2=CC=C(NC(N)=O)C=C2)NC([C@H](CC3=CC=C(NC([C@H](CC(N4)=O)NC4=O)=O)C=C3)NC([C@H](CO)NC([C@@H](CC5=CC=CN=C5)NC([C@@H](CC6=CC=C(Cl)C=C6)NC([C@@H](CC7=CC=C8C=CC=CC8=C7)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	FE 200486 (free base)
Shipping condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; GnRH Receptor
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Molecular Weight	1632.26
Product Description	Degarelix acetate (FE 200486) is a decapeptide that shows high affinity/selectivity to human gonadotropin-releasing hormone (GnRH) receptor (IC50 = 3 nM). Degarelix acetate Degarelix acetate (FE 200486) is used for the research of prostate cancer[1][2].
Manufacturer - Research Area	Cancer; Endocrinology
Solubility	DMSO : 10 mg/mL (ultrasonic)\|H2O : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; GPCR/G Protein
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16168A-100mg-safety-datasheet.pdf